Binimetinib (MEK162) in recurrent low-grade serous ovarian cancer resistant to chemotherapy and hormonal treatment
Background: Management of advanced/recurrent low-grade serous ovarian carcinoma (LGOSC) is often challenging. Effective treatment options remain limited for hormone and chemotherapy-resistant LGSOC.CASE: A 65-year-old woman with recurrent widespread LGSOC harboring the KRAS-G12 V hotspot mutation ex...
Saved in:
| Main Authors: | , , , , |
|---|---|
| Format: | Book |
| Published: |
Elsevier,
2018-08-01T00:00:00Z.
|
| Subjects: | |
| Online Access: | Connect to this object online. |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Internet
Connect to this object online.3rd Floor Main Library
| Call Number: |
A1234.567 |
|---|---|
| Copy 1 | Available |